|
KMID : 0363320170380010072
|
|
Journal of Korean Oriental Internal Medicine
2017 Volume.38 No. 1 p.72 ~ p.80
|
|
|
A Case of Patient with Recurring Non-Small Cell Lung Carcinoma Treated with Samchilchoongcho-Jung in Conjunction with Afatinib
|
|
Kim Jee-Hye
Bae Kyeo-Re
Park So-Jung
Cho Chong-Kwan
Yoo Hwa-Seung
|
|
|
Abstract
|
|
|
Objective: The purpose of this study is to report the case of a patient with recurring non-small cell lung carcinoma (NSCLC) taking Samchilchoongcho-Jung with Afatinib.
Methods: An NSCLC patient diagnosed with multiple bone and pulmonary metastasis was taking Afatinib (20 mg/day) and suffering from stomatitis caused by the Afatinib. The patient was treated with Samchilchoongcho-Jung (1,500 mg/day) for 3 months. The tumor size was measured with computed tomography, and laboratory findings, including tumor markers (CEA, Cyfra 21-1), were also followed up. Stomatitis was measured by a numeric rating scale, and adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.
Results: After combined treatment, stable disease was shown on computed tomography. The tumor marker levels of CEA and Cyfra 21-1 were decreased, and the stomatitis significantly improved. NCI-CTCAE 4.0 showed no adverse events.
Conclusion: This case study suggests that Samchilchoongcho-Jung may have a synergic effect, in conjunction with Afatinib, on the treatment of patients with recurring NSCLC.
|
|
|
KEYWORD
|
|
|
non-small cell lung carcinoma, Afatinib, Samchilchoongcho-Jung, epidermal growth factor receptor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|